Beijing Minhai Biotechnology Co.
Biotechnology company focused on vaccine research, development and manufacturing. Located in the Daxing Biomedical Industrial Base in Beijing. Operates R&D centers, pilot and commercial production lines, analytical quality evaluation platforms, and cold-chain fill-finish capabilities. Pipeline includes multiple conjugate, multivalent and other vaccine candidates at preclinical, clinical and registration stages. The company is developing a large vaccine production and R&D campus with multiple GMP-standard workshops and public service platform functions.
Industries
Nr. of Employees
large (251-1000)
Beijing Minhai Biotechnology Co.
No. 35, Simiao Road, Daxing Biomedical Industrial Base, Zhongguancun Science Park, Daxing District, Beijing
Patents
Engineered Hansenula fungi efficiently expressing CA10 virus-like particles and uses thereof
US-12251435-B2
View DetailsPurification of recombinant EV71 virus-like particle and method for preparing vaccine thereof
US-10987416-B2
View Details
Engineered Hansenula fungi efficiently expressing CA10 virus-like particles and uses thereof
US-12251435-B2
View DetailsPurification of recombinant EV71 virus-like particle and method for preparing vaccine thereof
US-10987416-B2
View DetailsProducts
Pneumococcal polysaccharide vaccine (23-valent)
Manufacture and commercial launch of a 23-valent pneumococcal polysaccharide vaccine product.
Rabies vaccine (human diploid cell, lyophilized)
Production line and industrialization project for human diploid cell rabies vaccine (freeze-dried injections) with annual capacity targets described in project disclosures.
Inactivated poliomyelitis vaccine (sIPV, liquid)
Reported liquid inactivated polio vaccine production line and associated capacity in R&D/production building disclosures.
Pneumococcal polysaccharide vaccine (23-valent)
Manufacture and commercial launch of a 23-valent pneumococcal polysaccharide vaccine product.
Rabies vaccine (human diploid cell, lyophilized)
Production line and industrialization project for human diploid cell rabies vaccine (freeze-dried injections) with annual capacity targets described in project disclosures.
Inactivated poliomyelitis vaccine (sIPV, liquid)
Reported liquid inactivated polio vaccine production line and associated capacity in R&D/production building disclosures.
Services
Commercial-scale production and fill-finish services for multiple vaccine types, including pre-filled syringe workflows.
Finished product cold storage and logistics support for vaccine distribution; public notices for entrusted storage and distribution.
On-site R&D center and shared pilot-scale platforms intended to support external R&D institutions and small- and medium-sized biomedical enterprises.
Commercial-scale production and fill-finish services for multiple vaccine types, including pre-filled syringe workflows.
Finished product cold storage and logistics support for vaccine distribution; public notices for entrusted storage and distribution.
On-site R&D center and shared pilot-scale platforms intended to support external R&D institutions and small- and medium-sized biomedical enterprises.
Expertise Areas
- Vaccine research and platform development
- Conjugate and multivalent vaccine development
- Clinical development and trial management
- Commercial and pilot-scale vaccine manufacturing
Key Technologies
- Conjugate vaccine production methods
- Recombinant protein vaccine production
- Multivalent vaccine platform design
- Oral vaccine formulation technologies
News & Updates
Summary and commentary on a draft vaccine management law proposing full-chain vaccine management, mandatory liability insurance, stricter production access, batch issuance systems, traceability and strengthened supervision.
Announcement that the Daxing District project received a construction preparation letter; describes the planned international vaccine industrial base covering 135 mu with an R&D center and 16 GMP-standard production workshops, and intended public service platform functions.
Article describing R&D achievements and referencing the parent company vaccine portfolio and R&D efforts (includes overview of product types and projects).
Announcement of commercial launch of a 23-valent pneumococcal polysaccharide vaccine.
Public notice of the environmental impact assessment and public consultation for construction of workshops including a 13-valent pneumococcal conjugate vaccine workshop; describes emissions control, wastewater routing to existing treatment stations, and public comment procedures and timelines.
Monthly monitoring results for wastewater discharge parameters with compliance status against local standards.
Summary and commentary on a draft vaccine management law proposing full-chain vaccine management, mandatory liability insurance, stricter production access, batch issuance systems, traceability and strengthened supervision.
Announcement that the Daxing District project received a construction preparation letter; describes the planned international vaccine industrial base covering 135 mu with an R&D center and 16 GMP-standard production workshops, and intended public service platform functions.
Article describing R&D achievements and referencing the parent company vaccine portfolio and R&D efforts (includes overview of product types and projects).
Announcement of commercial launch of a 23-valent pneumococcal polysaccharide vaccine.
Public notice of the environmental impact assessment and public consultation for construction of workshops including a 13-valent pneumococcal conjugate vaccine workshop; describes emissions control, wastewater routing to existing treatment stations, and public comment procedures and timelines.
Monthly monitoring results for wastewater discharge parameters with compliance status against local standards.